Many of the aforementioned studies, with different methods, have proved that SGLT2 inhibitors can affect the cardiac energy metabolism substrate changes to increase the expressions of AMPK and Sirt1 and improve energy supply efficiency to improve heart function, and the experimental results of HF rats by EMPG treatment before and after the expression of AMPK, with increased Sirt1, further verified that EMPG can not only improve the cardiac energy efficiency of DM rats but also showed the same effect in HF rats. The gene discussed is SLC5A2; the disease is hydrops fetalis.